PEG

Tos-PEG2-Boc is a PEG-based linker for PROTACs, joining two essential ligands crucial for forming PROTAC molecules. This linker enables selective protein degradation by leveraging the ubiquitin-proteasome system within cells.

Tos-PEG4-acid is a PEG-based linker for PROTACs that joins two essential ligands, crucial for forming PROTAC molecules, enabling selective protein degradation by leveraging the ubiquitin-proteasome system within cells.

Tos-PEG5-Boc is a PEG-based linker for PROTACs that connects two essential ligands, facilitating the formation of PROTAC molecules. This linker enables selective protein degradation by leveraging the ubiquitin-proteasome system within cells.

Tos-PEG6-C2-Boc, a PEG-based linker for PROTACs, connects two essential ligands critical for forming PROTAC molecules and facilitates selective protein degradation by utilizing the ubiquitin-proteasome system [in cells].

Tos-PEG6-CH2-Boc, a PEG-based linker for PROTACs, connects two essential ligands critical for forming PROTAC molecules, enabling selective protein degradation via the ubiquitin-proteasome system within cells.

VH032-PEG3-acetylene is a synthesized conjugate compound comprising a VH032-based VHL ligand and a linker, intended for use in PROTAC technology as an E3 ligase ligand-linker conjugate[1].

1,1,1-Trifluoroethyl-PEG2-propargyl is a polyethylene glycol (PEG) derivative specifically designed to serve as a PROTAC linker in the synthesis of PROTACs[1].

2-((Azido-PEG8-carbamoyl)methoxy)acetic acid is a polyethylene glycol (PEG) derivative used as a linker in the synthesis of proteolysis targeting chimeras (PROTACs) [1].

(2-Pyridyldithio)-PEG4 acid is a four-unit cleavable polyethylene glycol (PEG) linker specifically designed for the synthesis of antibody-drug conjugates (ADCs)[1]. It serves as a crucial component in the conjugation of antibodies and drugs, enabling targeted drug delivery and enhanced therapeutic efficacy. This linker possesses a (2-pyridyldithio) group at one end, facilitating the attachment of the linker to the specific site on the antibody molecule. The PEG4 chain provides the necessary flexibility and biocompatibility for optimal drug release while maintaining stability throughout the circulation in the body. Ultimately, (2-Pyridyldithio)-PEG4 acid is instrumental in the development and advancement of ADCs, a promising approach in cancer therapy.